BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price target hoisted by equities research analysts at Wells Fargo & Company from $100.00 to $110.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price objective would suggest a potential […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) had its price objective boosted by analysts at Wells Fargo & Company from $100.00 to $110.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target would […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided EPS guidance of $2.75-2.95 for the period, compared to the consensus EPS estimate of $2.59. The company issued revenue guidance of $2.7-2.8 billion, compared to the consensus revenue estimate of $2.75 billion. BioMarin Pharmaceutical […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus earnings per share estimate of 1.650. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue […]
Linden Thomas Advisory Services LLC lowered its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 17,883 shares of the biotechnology company’s stock after selling 166 shares during the period. Linden Thomas Advisory Services LLC’s holdings in BioMarin Pharmaceutical were worth $1,724,000 […]